Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Files Next HIV Triple-Combo Pill, With Hopes Of Prophylaxis Claim; Can Firm Recreate HIV Success In Hep C?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Gilead Sciences, Inc. has filed an NDA for a triple-combination HIV pill that could supplant its existing Atripla, which will face generic pressure in 2013. The company announced Nov. 23 that it has filed for FDA approval of a single-tablet regimen containing its Truvada (emtricitabine/tenofovir) plus Johnson & Johnson's investigational non-nucleoside reverse transcriptase inhibitor rilpivirine, also known as TMC278.

You may also be interested in...

Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up

Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.

Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV

Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna

Moderna CEO Pushes Back On Trump Debate Comments On COVID Vaccine, Offers Own Timeline

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts